The patients with SPEN mutant cancer (median, 19.63; interquartile range, 5.3–49.86) had higher TMB than patients without SPEN mutant cancer (1.9, 0.9–4.1; P < 0.0001) in the TCGA cohort (Fig. 6A). The gene discussed is SPEN; the disease is cancer.